Original news and analysis on international IP policy
IRVINE, CALIFORNIA – Experts gathered here last week addressed the question of – one year later - what does the United States Supreme Court’s decision on human gene patents mean for scientific research and patent policy?
Intellectual property and the issues of biotechnology and public health are rising concerns for stakeholders to the Trans-Pacific Partnership agreement negotiations.
Investor agreements, included in many bilateral investment treaties (BITs), are a source of growing concern for many national governments. These agreements essentially leave countries vulnerable to litigation by individual firms, rather than other countries, as is the case in traditional World Trade Organization disputes.
Intellectual property and product branding can be valuable tools for development, and communities and countries are taking note, according to the World Intellectual Property Organization, which held a presentation on the issue yesterday.
The United Nations Economic and Social Council (ECOSOC) yesterday took action on reports pertaining to HIV/AIDS, noncommunicable diseases (NCDs), and science and technology for development.
The landscape and nature of world trade are changing, and quickly, according to the latest World Trade Report published by the World Trade Organization. Technological innovation, shifts in production and consumption patterns, and demographic change are said to be the primary factors that will shape the future of world trade and the global trading system, the report found.
Despite last month’s United States Supreme Court decision on a case involving Myriad Genetics, which struck down some of Myriad’s patents related to human genes, Myriad has filed infringement suits against two companies that had announced they would begin offering lower-cost tests for the breast cancer genes in question.
Small-scale farmers and their role in food security are a “missing element” in the draft articles being reviewed at this week’s negotiations at WIPO, according to a briefing paper issued by the Quaker United Nations Office (QUNO).
Decline in pharmaceutical research and development productivity is one of the main challenges addressed in the 2013 edition of the World Health Organization report, Priority Medicines for Europe and the World. Whether the decline in pharmaceutical R&D is due to R&D depletion, overly strict regulatory hurdles, or the current pharmaceutical business model remains unanswered.
The themes of innovation, collaboration, and policy coherence shared the spotlight during panel discussions at the 5 July technical symposium on Medical Innovation: Changing Business Models. The event was jointly hosted by the World Health Organization, World Intellectual Property Organization, and World Trade Organization.